Formation of pyridinium species of haloperidol in human liver and brain

Psychopharmacology

Volumn 125, Issue 3, 1996, Pages 214-219

  Eyles, Darryl W ^a,b   McGrath, John J ^a   Pond, Susan M ^b  

^a WOLSTON PARK HOSPITAL   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; brain metabolism; cytochrome P 450; cytosol; drug metabolism; haloperidol; HPP+ haloperidol pyridinium derivative; human tissue; ketone reductases; mitochondria; neurotoxin; reduced haloperidol; RHPP+ reduced haloperidol pyridinium derivative

Indexed keywords

CLORGYLINE; CYTOCHROME P450 ISOENZYME; DAUNORUBICIN; DEBRISOQUINE; DRUG METABOLITE; HALOPERIDOL; KETOCONAZOLE; KETONE REDUCTASE; MENADIONE; MONOAMINE OXIDASE INHIBITOR; PARGYLINE; PROADIFEN; PYRIDINIUM DERIVATIVE; QUINIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SELEGILINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN; CELL FRACTIONATION; CONTROLLED STUDY; CYTOSOL; DRUG METABOLISM; FEMALE; HUMAN; HUMAN TISSUE; LIVER; MALE; MICROSOME; MITOCHONDRION; NEUROTOXICITY; OXIDATION; PRIORITY JOURNAL; REDUCTION; SCHIZOPHRENIA;

ADOLESCENT; BRAIN; DOPAMINE ANTAGONISTS; HALOPERIDOL; HUMANS; LIVER; MALE; MIDDLE AGED; PYRIDINIUM COMPOUNDS; SUBCELLULAR FRACTIONS;

EID: 0029935965     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02247331     Document Type: Article

References (26)

1. Bachur NR (1976) Cytoplasmic aldo-keto reductases: a class of drug metabolising enzymes. Science 193:595-597
2. Bloomquist J, King E, Wright A, Mytilineou C, Kimura K, Castagnoli K, Castagnoli Jr N (1994) 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies. J Pharmacol Exp Ther 270:822-830
3. Bocker RH, Guengerich FP (1986) Oxidation of 4-aryl- and 4-alkyl-substituted 2,6-dimethly-3,5-bis(alkoxycarbonyl)-1,4-dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450. J Med Chem 29:1596-1603
4. Eyles DW, Pond SM (1992) Stereospecific reduction of haloperidol in human tissues. Biochem Pharmacol 44:867-871
5. Eyles DW, McLennan HR, Jones A, McGrath JJ, Stedman TJ, Pond SM (1994a) Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia. Clin Pharmacol Ther 56:512-520
6. Eyles DW, Stedman TJ, Pond SM (1994b) Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: evaluation of possible mechanisms. Psychopharmacology 116:161-166
7. Fang J, Gorrod JW (1993) High performance liquid chromatographic method for the detection and quantitation of haloperidol and seven of its metabolites in microsomal preparations. J Chromatogr 614:267-273
8. Forsman A, Folsch G, Larsson M, Ohman R (1977) On the metabolism of haloperidol in man. Curr Ther Res 21:606-617
9. Ghersi-egea J-F, Perrin R, Leininger-Muller B, Grassiot M-C, Jeandel C, Floquet J, Cuny G, Siest G, Minn A (1993) Subcellular location of cytochrome P450, and activities of several enzymes responsible for drug metabolism in the human brain. Biochem Pharmacol 45:647-658
10. Gorrod JW, Fang J (1993) On the metabolism of haloperidol. Xenobiotica 23:495-508
11. Guengerich FP (1990) Mechanism-based inactivation of liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 3:363-371
12. Halpert JR, Guengerich FP, Bend JR, Correia MA (1994) Selective inhibitors of cytochromes P450. Toxicol Appl Pharmacol 125: 163-175
13. Igarashi K, Castagnoli Jr N (1992) Determination of the pyridinium metabolite derived from haloperidol in brain tissue, plasma and urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr 579:277-283
14. Korpi ER, Kleinman JE, Costakos DT, Linnoila M, Wyatt RJ (1984) Reduced haloperidol in the post-mortem brains of haloperidol-treated patients. Psychiatry Res 11:259-269
15. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980
16. Lerena AL, Alm C, Dahl M-L, Ekqvist B, Bertilsson L (1992) Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 14:92-97
17. Lowry OH, Rosebrough NJ, Harr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275
18. Oida T, Terauchi Y, Yoshida K, Kagemoto A, Sekine Y (1989) Use of antisera in the isolation of human specific conjugates of haloperidol. Xenobiotica 19:781-793
19. +-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J Pharmacol Exp Ther 268: 380-387
20. Someya T, Shibasaki M, Noguchi T, Takahashi S, Inaba T (1992) Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction. J Clin Psychopharmacol 12:169-174
21. Spina E, Ancione M, Di Rosa AE, Meduri M, Caputi AP (1992) Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur J Clin Pharmacol 42:347-348
22. Stedman TJ, Whiteford HA Eyles DW, Welham JL, Pond SM (1991) Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients. J Clin Psychopharmacl 11:43-47
23. Subramanyam B, Rollema H, Woolf T, Castagnoli Jr N (1990) Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem Biophys Res Commun 166: 238-244
24. Subramanyam B, Woolf T, Castagnoli Jr N (1991) Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite. Chem Res Toxicol 4:123-128
25. Tipton KF, Singer TP (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61:1191-1206
26. Van der Schyf CJ, Castagnoli K, Usuki E, Fouda HG, Rimoldi JM, Castagnoli Jr N (1994) Metabolic studies of haloperidol and its tetrahydropyridine analog in C57BL/6 mice. Chem Res Toxicol 7:281-285